Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Priovant Therapeutics

Tracked across 2 events · 23 articles · First seen Apr 02, 2026 · Last active Aug 26, 2026

Sentiment
45
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 70
Tech
Impact: Priovant Therapeutics is the developer of brepocitinib and the sponsor of the VALOR trial. The publication of positive skin-specific outcomes enhances the drug's clinical profile and supports its regulatory and commercial prospects.
Aug 26, 2026 · 7 articles
4 20
Business
Impact: Priovant Therapeutics, a subsidiary of Roivant Sciences, is expanding its brepocitinib development program into lichen planopilaris, which is a positive development for the company.
Apr 02, 2026 · 16 articles
ERGEN INTELLIGENCE
Track Priovant Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.